Novo Says It’s Likely to Benefit From Bristol-Amylin Tie-Up

Novo Nordisk A/S predicts it will benefit from Bristol-Myers Squibb Co.’s $5.3 billion purchase of Amylin Pharmaceuticals Inc. as their promotion of diabetes products may increase demand for Novo’s own range.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.